Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville 41013, Spain.
Antiviral Res. 2012 Sep;95(3):207-11. doi: 10.1016/j.antiviral.2012.06.007. Epub 2012 Jun 27.
The maraviroc clinical test (MCT) is a clinical approach to establish the indication of maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a combined antiretroviral therapy (cART) selected according to MCT results. Ninety-two consecutive HIV-infected patients underwent MCT. A virological response (<40 HIV-RNA copies/ml after 24 weeks) was observed in 76/92 patients (82.6%). These patients (n=76) were included in a time to treatment failure analysis; after a mean follow-up period of 88 weeks, treatment failure was confirmed in 14 patients (18.4%). Tropism switch during MCT was observed in 3/35 patients (8.6%); these patients experienced excellent long-term outcome on cART. In conclusion, MCT should be considered as an additional method before CCR5-antagonists prescription.
马拉维若治疗试验（MCT）是一种临床方法，用于确定马拉维若治疗的适应证。在本研究中，我们分析了根据 MCT 结果接受联合抗逆转录病毒治疗（cART）的患者的长期结局。92 例连续的 HIV 感染患者接受了 MCT。76/92 例患者（82.6%）观察到病毒学应答（24 周后<40 HIV-RNA 拷贝/ml）。这些患者（n=76）被纳入治疗失败时间分析；在平均 88 周的随访后，14 例患者（18.4%）确诊治疗失败。在 35 例患者中的 3 例（8.6%）在 MCT 期间观察到病毒学耐药；这些患者在 cART 上获得了良好的长期结局。总之，在使用 CCR5 拮抗剂之前，MCT 应被视为一种额外的方法。
